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ABSTRACT 
Analgesic and Anti-Inflammatory Effects of Monoacylglycerol Lipase Inhibition in Mice 
Subjected to Collagen-Induced Arthritis 
Sara R. Nass 
Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease, affecting 
approximately 1% of the world population. This autoimmune disease is characterized by pain, 
stiffness, swelling, and breakdown of cartilage in synovial joints. Current RA analgesic 
treatments (i.e., pain reducing drugs) are ineffective or induce negative side effects, and so there 
are many concerted efforts to discover new RA treatments. Cannabinoids have analgesic and 
anti-inflammatory properties; however, the challenge remains to harness the medical potential of 
cannabinoids without inducing negative psychoactive effects (e.g., cognitive deficits, emotional 
disruption, and abuse potential). An alternative approach focuses on the endogenously produced 
cannabinoids (endocannabinoids). The endocannabinoids 2-arachidonoyl glycerol (2-AG) and 
anandamide are catabolized by the enzymes monoacylglycerol lipase (MAGL) and fatty acid 
amide hydrolase (FAAH), respectively. Pharmacological inhibition of MAGL or FAAH increases 
brain levels of the respective endocannabinoids, 2-AG or anandamide, and significantly 
decreases inflammatory pain. The present study tested the hypothesis that MAGL inhibition 
decreases hyperalgesia, locomotor suppression, and allodynia caused by collagen-induced 
arthritis (CIA), a well-established animal model of inflammatory arthritis. Separate groups of 
mice subjected to CIA were administered acute or chronic doses of the selective MAGL inhibitor 
JZL184 and tested for (1) thermal hyperalgesia in the hotplate and tail immersion tests, (2) 
mechanical allodynia, and (3) suppressed locomotor activity. Thermal hyperalgesia was 
significantly attenuated by acute JZL184 (8 or 40 mg/kg) in the hot plate test, but not the tail 
immersion test. The lack of JZL184 attenuation of hyperalgesia in the tail immersion test may 
indicate a JZL184 supraspinal mechanism of action. Although the present study was hampered 
by ongoing model development, these results suggest that MAGL inhibition may be a promising 
strategy for the treatment of pain caused by inflammatory arthritis. 
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 The term "arthritis" encompasses over 100 different medical conditions (CDC, 2012) and 
can be broadly divided into two different categories: musculoskeletal and inflammatory arthritis. 
Rheumatoid arthritis (RA) is the most common type of inflammatory arthritis, affecting about 
1% of the population worldwide (Firestein, 2003). RA is a systemic inflammatory disease 
categorized by swelling and erosion of multiple synovial joints (i.e., knees, elbows, wrists, hips, 
and fingers) (CDC, 2012). Other symptoms of RA, caused by systemic inflammation, include 
anemia, fatigue, generalized bone loss, artherosclerosis, and lung tissue damage (Moreland, & 
Curtis, 2008). Although the etiology of RA is not well understood, it is considered an 
autoimmune disease, in that the host's immune system attacks healthy tissues, causing localized 
inflammation and tissue damage (Boissier et al., 2012). During the autoimmune process, there is 
a release of proinflammatory mediators (i.e., cytokines and chemokines) that increase 
nociception (i.e., pain) by either directly activating nociceptors or producing a sensitization of 
the somatosensory nervous system that leads to an increase in inflammation and pain (Scholz & 
Woolf, 2002). 
 In addition to being the primary negative symptom among RA patients, increased 
nociception contributes directly to chronic disability by limiting mobility. Perhaps surprisingly, 
RA patients report chronic pain, rather than joint damage, as the primary reason for their limited 
mobility and decreased quality of life (Lee, 2013). Chronic pain also causes psychological and 
physiological distress, which can negatively affect disease outcome. For example, during the 
early stages of the disease, patients who rate overall pain as "high" report increased levels of 
disability one year later, as compared with patients who rate their pain as relatively lower (Walsh 
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& McWilliams, 2012). Chronic pain can also cause patients to forgo physical activities that may 
otherwise be beneficial to their physical and emotional health. The pain, as well as fatigue 
induced by sleep disturbance, can then lead to decreased productivity (Walsh & McWilliams, 
2012). Mood disturbance can also affect chronic pain patients. Pain causes depression, and then 
the altered affect makes it increasingly difficult to cope with the pain, thus causing a vicious 
cycle. In other words, in addition to the pain itself, decreased physical activity and increased 
mood and sleep disturbance also lead to an immeasurable decrease in the quality of life of 
patients suffering from RA. What is perhaps easier to quantify is the cost of RA to the US 
healthcare system, which is staggering with $545 million spent in 2009 alone, on hospital visits 
directly related to this disease (CDC, 2012). 
 The main cause of widespread pain in RA patients is chronic inflammation of the 
synovium, which is the smooth lining of the joint. In the acute inflammatory phase, 
inflammatory mediators elicit local inflammation by activating neutrophils, which are a type of 
short-lived white blood cells that play a major role in the innate immune response. When 
inflammation becomes chronic, as with RA, the neutrophils are replaced by macrophages and T-
cells at the site of inflammation (Medzhitov, 2008). Macrophages (literally "big eater" cells) are 
relatively long-lived white blood cells that ingest foreign bodies and produce proinflammatory 
cytokines (e.g., tumor necrosis factor (TNF), interleukin-1 (IL-1), gamma interferon (IFNγ) and 
interkeukin-6 (IL-6)) and chemokines. Proinflammatory cytokines function to modulate the 
inflammatory response, and chemokines recruit other inflammatory cells to the site. In addition 
to increasing localized inflammation to attack the joint tissue, these signaling molecules help to 
orchestrate differentiation and maturation of B-cells, which produce antibodies against the target 
tissue, thus further exacerbating the inflammatory immune response (Scrivo, Franco, Spadaro, & 
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Valesini, 2007). The abundance of T-cells, macrophages, and pro-inflammatory cytokines (TNF, 
IL-1, and IL-6) found in the synovial fluid of RA patients supports this cell-mediated 
autoimmune process as a mechanism for chronic inflammation in RA (Boissier et al., 2012). 
Current Rheumatoid Arthritis Treatments 
 To date, the main foci of treating RA have been to (1) reduce the proinflammatory 
immune response, and (2) reduce RA associated pain. Disease-modifying antirheumatic drugs 
(DMARDs) and glucocorticoids (steroids) are popular treatments. Despite the effectiveness of 
these medications in suppressing the disease progression, they also evoke harmful side effects 
and are often ineffective in reducing pain. For example, when introduced later in the disease 
progression, DMARDs are generally ineffective as analgesics. Even when introduced early, 
many patients report the presence of moderate pain regardless of DMARD treatment (Lee, 
2013). Similarly, steroids such as glucocorticoids are effective analgesics when administered in 
the short-term, but this analgesia quickly abates as the patient builds tolerance to the steroids 
(Lee, 2013). Perhaps more alarming is that chronic glucocorticoid treatment can induce 
insensitivity to one's own steroid hormones (Dinsen, 2013), which can lead to many side effects, 
including dysregulated immune function on a broad scale. In severe cases where DMARDs or 
glucocorticoids are ineffective in slowing the progression of the disease, biologic therapies that 
suppress specific cytokine responses (i.e., TNF, IL-1, & IL-6) are often used (Al-Shakarchi, 
Gullick, & Scott, 2013). However, as with steroid treatments, cytokines mediate many different 
cell types and functions, and so these drugs are somewhat non-selective and can cause negative 
side effects along with decreased analgesic efficacy over time (Barton, 2008). Furthermore, any 
immunosuppressive treatment has the potential to leave the patient with an increased 
vulnerability to infection.  
Analgesic Effects in Collagen-Induced Arthritis   7 
 
 Due to the side effects detailed above, nonsteroidal anti-inflammatory drugs (NSAIDS) 
have become increasingly popular for attenuating inflammatory pain, with comparatively fewer 
side effects than the alternatives listed above (Lee, 2013). Nevertheless, NSAIDs are not without 
risk. Chronic NSAID use can cause gastrointestinal bleeding, renal impairment, and increased 
risk of cardiovascular events, all of which are potentially life threatening (Walsh & McWilliams, 
2012). The increased cardiovascular risk of NSAIDs may be especially problematic for patients 
with RA, who already have an increased cardiovascular risk, as compared with the general 
population (Walsh & McWilliams, 2012).  
The Endocannabinoid System 
 Due to the adverse impact that chronic pain has on patients’ lives, many choose self-
medication with drugs of abuse, most commonly with Cannabis sativa. Cannabis has been used 
to treat a variety of ailments, including pain, for thousands of years (Mechoulam & Parker, 
2013). Cannabis and similar compounds (cannabinoids) have anti-inflammatory properties and 
also elicit antinociceptive effects by inhibiting neuronal transmission in pain pathways. 
Cannabinoid induced analgesia (i.e., pain reduction) has been reported in a variety of clinical and 
preclinical pain models (Guidon & Hohmann, 2009). In addition to chronic pain, Cannabis also 
has analgesic and immunomodulatory effects in a variety of diseases such as multiple sclerosis, 
AIDS, and amyotrophic lateral sclerosis (Kogan & Mechoulam, 2007). In the 1960s, the main 
psychoactive component of Cannabis, Δ
9
-tetrahydrocannabinol (THC), was isolated and 
synthesized (Gaoni & Mechoulam, 1964). However, the undesirable psychomimetic side effects, 
including deficits in attention and cognitive function, coupled with the abuse potential of THC 
and other exogenous cannabinoids decrease enthusiasm to use these drugs as therapeutic 
analgesics (Crowe, Nass, Gabella, & Kinsey, 2014). Instead, a rapidly growing body of research 
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indicates that the endogenous cannabinoid (i.e., "endocannabinoid") system may offer promising 
new targets for pain treatment.  
 There are two endocannabinoid (eCB) receptors that have been identified and cloned: 
cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). The CB1 receptor is expressed 
throughout the body and mediates most of the psychoactive effects of cannabinoid agonists, 
including hypothermia, catalepsy, and cognitive deficits (Crowe et al., 2014; Nass et al., 2015; 
Herkenham, Lynn, Johnson, Melvin, de Costa, & Rice, 1991). The CB1 receptor is also expressed 
in central nervous system (CNS) areas associated with pain (i.e. the amygdala, periaqueductal 
gray, and dorsal horn of the spinal cord), indicating that the eCB system is located in appropriate 
areas to modulate pain (Schlosburg, et al., 2009). On the other hand CB2 is expressed mainly in 
immune tissues, but can also be found in the CNS on microglia (the macrophages of the CNS) 
and in low levels in the brainstem (Mechoulam & Parker, 2013). Within the immune system, 
CB2 is expressed on a variety of cells (i.e. B cells, natural killer cells, monocytes, neutrophils, 
and other lymphocytes) with different levels of expression depending on the activation state of 
the cell and the type stimulation (Rom & Persidsky, 2013). There are two major 
endocannabinoids: N-arachidonoylethanolamine (AEA; anadamide) and 2-arachidonoylglycerol 
(2-AG), that activate and bind to both CB1 and CB2 (Mechoulam & Parker, 2013).  
 Unlike other neurotransmitters, which are stored in vesicles, endocannabinoids are 
synthesized de novo and then rapidly metabolized by enzymes, thus resulting in a short span of 
activity. Anandamide is primarily regulated by fatty acid amide hydrolase (FAAH) and 2-AG is 
predominately regulated by monoacylglycerol lipase (MAGL; Figure 1) (Mechoulam & Parker, 
2013). Due to its rapid metabolism MAGL, it is impractical to exogenously administer 2-AG as 
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therapeutic treatment. However, pharmacological inhibition or genetic deletion of MAGL 
increases the endogenous levels of 2-AG and results in analgesia (Long et al., 2009).  
 FAAH and MAGL inhibition attenuates analgesia in animal models of acute 
inflammatory pain. Administration of the FAAH inhibitor URB597 attenuates hyperalgesia in 
the complete Freund’s adjuvant (CFA) model of acute inflammatory pain (Schlosburg et al., 
2009). CFA is an emulsion of paraffin oil containing a surfactant and heat killed Mycobacterium 
tuberculosis that induces an inflammatory response, without the development of tuberculosis 
(Billiau & Matthys, 2001). URB597 also attenuates hyperalgesia and edema caused by 
intraplantar injection (into the ventral footpad) of the bacterial endotoxin lipopolysacharride 
(Naidu, Kinsey, Guo, Cravatt, Lichtman, 2010). Similarly, intraplantar injection of the seaweed 
extract carrageenan elicits localized edema and thermal and tactile hyperalgesia in mouse paws 
that is attenuated by URB597 administration (Schlosburg et al., 2009). The carrageenan 
inflammatory model has also been used very recently to evaluate the analgesic and anti-
inflammatory effects of MAGL inhibition. Carrageenan is a seaweed extract and common food 
additive that, when injected, causes localized pain and inflammation. The MAGL inhibitor 
JZL184 attenuates carrageenan-induced acute paw edema inflammatory pain (Ghosh et al., 
2013). Thus, there is evidence to support the idea that MAGL inhibition may also reduce 
inflammatory pain in a chronic model such as inflammatory arthritis. 
Inflammatory Arthritis Model 
 Animal models of rheumatoid arthritis are used to increase the understanding of the 
pathogenesis of the disease and evaluate potential therapeutic treatments. The best characterized 
mouse model of rheumatoid arthritis is collagen-induced arthritis (CIA). In the CIA paradigm, 
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mice are injected with an emulsion of type II bovine collagen mixed with an equal part of 
complete Freund’s adjuvant (Brand, Latham, & Rosloniec, 2007; Kinsey, Naidu, Cravatt, 
Dudley, & Lichtman, 2011a). Four to eight weeks after the initial immunization, mice show 
clinical signs of arthritis (e.g., paw swelling, redness) as well as cartilage destruction, 
ossification, pronounced synovitis, and periarticular inflammation (Brand et al., 2007; Inglis, 
Simelyte, McCann, Criado, & Williams, 2008). During the progression of arthritis, T-cell, pro-
inflammatory cytokines, and anti-collagen antibody responses increase (Brand et al., 2007; Inglis 
et al., 2008). Although the progression of CIA is more rapid than in the human disease (Bendele, 
2001), both mice and RA patients have the extensive pannus (i.e., irregular tissue formation) 
associated with cartilage destruction and increased t-cell and pro-inflammatory cytokine 
response in their synovial joints. Due to the aforementioned similarities between RA and CIA the 
model has several advantages over other animal models of inflammatory arthritis. For example, 
the collagen-antibody-induced arthritis (CAIA) model is induced by transferring anti-collagen 
antibody and administering the gram-negative bacteria marker lipopolysaccharide (LPS) to mice 
(Khachigian, 2006). Unlike RA and CIA the CAIA model progresses on a rapid time course and 
does not involve T-cells in the pathogenesis (Khachigian, 2006; Asquith, Miller, McInnes, & 
Liew, 2009). T-cells are one of the main immune cells that are activated in RA (Boissier et al., 
2012). The TNF-α transgenic mouse model of arthritis is induced by an overexpression of human 
TNF-α. It has a similar pathogenesis to RA and CIA, but unlike RA and CIA the TNF-α model 
does not produce rheumatoid factor or involve T-cells (Bevaart, 2010). Rheumatoid factor is an 
antibody that develops against self-tissue and can be found in the serum and joint fluid of RA 
patients (Boissier et al., 2012). 
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 Despite the well-known anti-inflammatory and analgesic properties of cannabinoids, a 
paucity of research focuses on the effects of cannabinoids in CIA. Administration of exogenous 
cannabinoids attenuates clinical signs of arthritis and joint damage, while having an 
immunosuppressant effect in CIA (Malfait et al., 2000; Sumariwalla et al., 2004). The anti-
inflammatory and analgesic effects of anandamide have also been evaluated through FAAH 
inhibition in CIA. Administration of the FAAH inhibitor URB597 or genetic deletion of FAAH 
attenuates thermal hyperalgesia (sensitivity to noxious heat) in the hot plate and tail immersion 
tests in mice subjected to CIA. Furthermore, chronic FAAH inhibition reduces CIA-induced paw 
swelling and joint destruction (Kinsey et al., 2011a). Taken together, these studies indicate that 
cannabinoids and endocannabinoids attenuate CIA-induced pain and inflammation. However, the 
possible role of 2-AG is unknown.  
 2-AG is much more prevalent than anandamide in the CNS, and MAGL inhibition is 
relatively more potent than FAAH inhibition in models of neuropathic pain and gastric 
inflammation (Kinsey et al., 2009; Kinsey et al., 2011b). However, there are no reported data on 
the effects of MAGL inhibition on inflammatory arthritis. This is likely due to a historic lack of 
selective MAGL inhibitors or MAGL knockout (i.e., genetic deletion) mice. However, with the 
recent synthesis of highly selective MAGL inhibitors, it is now possible to investigate the 
efficacy of MAGL inhibition on inflammatory arthritis.  
 In the present studies, we investigated the analgesic and anti-locomotor suppressed 
behavioral effects of MAGL inhibition in the collagen-induced arthritis mouse model of 
inflammatory arthritis. First, we tested the hypothesis that acute treatment with the MAGL 
inhibitor JZL184 would reduce CIA-induced pain and locomotor suppression. To this end, we 
tested a range of doses of JZL184. In addition we tested the FAAH inhibitor PF-3845 and the 
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glucocorticoid dexamethasone as positive controls. FAAH inhibition attenuates CIA-induced 
thermal hyperalgesia (Kinsey et al., 2011a) and dexamethasone attenuates LPS-induced thermal 
hyperalgesia (Naidu et al., 2010). Second, we tested the hypothesis that the observed analgesic 
effects of JZL184 are mediated by the CB1 receptor. We pretreated mice that had been 
administered JZL184 with selective CB1 and CB2 receptor antagonists and then tested the mice 
for hyperalgesia, allodynia, and locomotor suppression. Third, we tested the hypothesis that 
chronic treatment with JZL184 or PF-3845 would reduce CIA-induced inflammation, 
hyperalgesia, and allodynia. We quantified the anti-inflammatory effects of MAGL and FAAH 
inhibition by measuring paw swelling and performing clinical scoring of arthritic changes, and 
then conducted behavioral assays. 
Statement of the Problem 
 Rheumatoid arthritis is a chronic autoimmune disease that decreases quality of life and is 
correlated with increased depression and sleep disturbances (Lee, 2013). Pain is the most salient 
symptom among patients with RA and also predicts longitudinal changes in disability over the 
disease progression (Walsh & McWilliams, 2012). Conventional treatments for inflammatory 
arthritis include immunosuppressant agents such as steroids and non-steroidal anti-inflammatory 
drugs (NSAIDs). However, these drugs have numerous negative side effects, including 
increasing patients’ susceptibility to infection.  
Current research focuses on the endocannabinoid system as a potential therapeutic target 
for inflammatory pain, because of the analgesic effects that are unaccompanied by 
psychomimetic effects (Schlosburg et al., 2009). Selective inhibitors of the two main metabolic 
enzymes of the endocannabinoid system (FAAH and MAGL) have been shown to reduce pain 
and inflammation in several animal models of inflammatory pain (Ghosh et al., 2013; Kinsey et 
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al., 2011a; Schlosburg et al., 2009). Our lab recently demonstrated that FAAH inhibition reduces 
the pain and inflammation caused by collagen-induced arthritis (Kinsey et al., 2011a). However, 
although 2-AG is expressed in the brain at approximately 200 fold higher levels than 
anandamide, there are no data on the possible analgesic and anti-inflammatory effects of MAGL 
inhibition, with regard to inflammatory arthritis. Therefore, we evaluated the possible analgesic 
and anti-inflammatory effects of MAGL inhibition in the collagen-induced arthritis mouse model 
of inflammatory arthritis. 
Methods 
Animals 
 Subjects were adult male DBA/1J mice (Jackson Laboratory, Bar Harbor, ME) that were 
9-10 weeks old at the start of the experiments. Mice were housed 3-5 per cage in a temperature 
(20-22°C) and humidity controlled environment with ad libitum access to food and water. Male 
DBA/1J mice were used because they are highly susceptible to developing CIA, as compared to 
females and other mouse strains (Bendele, 2001). In the acute studies, 18-90% of the mice 
developed arthritis and were used for testing. However, for the chronic dosing study, all mice 
were included and 98% developed arthritis. Mice were randomly assigned to treatment groups. 
All experimental protocols (14-1007) were approved by the Animal Care and Use Committee at 
West Virginia University. 
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Collagen Induced Arthritis (CIA) immunization 
In the CIA model, CFA is combined with collagen to induce a strong immune response in 
the presence of collagen. Then the “booster” re-exposure of collagen in IFA induces 
autoimmunity to self-collagen. Mice were anesthetized with isoflurane, and approximately 100 
µl of an emulsion consisting of bovine type II collagen (2 mg/ml), dissolved in 0.05 M acetic 
acid (Chondrex, Redmond, WA), in an equal volume of complete Freund’s adjuvant (CFA) (see 
Table 1) was injected intradermally approximately 1.5 cm from the base of the tail. Twenty-one 
days later, mice were given a secondary "booster" exposure to the collagen emulsion, but in an 
equal volume of incomplete Freund’s adjuvant (IFA), injected approximately 2 cm distal to the 
original injection. Freund’s adjuvants have been used since the 1940’s to facilitate the induction 
of animal models of autoimmune diseases. IFA consists of an emulsion of paraffin oil containing 
a surfactant. To become CFA, heat killed Mycobacterium tuberculosis is added to the emulsion 
to induce a strong immune response, without the development of tuberculosis (Billiau & 
Matthys, 2001). After the “booster” injection, paws were examined every few days for arthritic 
signs using a clinical scoring system as follows: 0, normal; 1, erythema and mild swelling 
confined to the ankle joint or toes; 2, erythema and mild swelling extending from the ankle to the 
midfoot or ankle joint; 3, erythema and moderate swelling extending from the ankle to the 
metacarpal/metatarsal joints; 4, erythema and severe swelling encompassing the ankle, foot, and 
digits (Kinsey et al., 2011a). The scores for the hind limbs were summed for each mouse, 
resulting in a composite arthritis score with a maximum of 8 total points. Foot thickness was also 
measured with a digital micrometer (Wixey WR100, Thermo Fisher Scientific, Inc.). The 
experimenter was blinded to treatments when scoring and measuring paws. Due to low incidence 
of arthritis in most experiments and ongoing model development, mice with a clinical score of 1 
Analgesic Effects in Collagen-Induced Arthritis   15 
 
or higher were used in the acute dosing experiments. Mice subjected to CIA that did not develop 
paw inflammation (i.e. clinical score of 0) were classified as non-responders and were not tested 
in acute dosing experiments. In the chronic dosing experiment all mice were used because it was 
impossible to determine if the lack of arthritic symptoms was due to non-responsiveness to CIA 
or drug effects. 
Table 1. Details of CIA induction protocol, by experiment. 
 
Drugs 
 The MAGL inhibitor JZL184 and the FAAH inhibitor PF-3845 were purchased from 
Cayman Chemical (Ann Arbor, MI). The CB1 antagonist rimonabant (SR141716A) and the CB2 
antagonist SR144528 were generously provided to Dr. Kinsey by the National Institute on Drug 
Abuse (Bethesda, MD). The synthetic glucocorticoid dexamethasone (DEX) was purchased from 
Sigma (St Louis, MO). All drugs were prepared in a vehicle of ethanol, Cremophor (Sigma-
Exp. Fig. Treatment Cohort Collagen M. Tb CFA Stopcock 
1a 
 
3 Acute JZL184 (8 & 40 mg/kg) 2 2 mg/ml 2 mg/ml Light No 
1a 
 
4 Acute JZL184 (1 & 4 mg/kg) 3 & 4 2 mg/ml 4 mg/ml Light No 
1b 
 




Acute Dexamethasone (2 





Acute SR1 or SR2 (3 mg/kg) 








Chronic JZL184  
(8 mg/kg) or PF-3845  
(10 mg/kg) 5 2 mg/ml 4 mg/ml Light Yes 
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Aldrich, St Louis, MO), and saline in a ratio of 1:1:18 parts. All solutions were administered at 
room temperature in a volume of 10 µl/g body weight.  
Experimental Plan  
 The goal of the first experiment was to determine the analgesic and anti-locomotor 
suppression effects of acute JZL184 administration. In experiment 1a, divided into two parts, we 
tested a dose range of JZL184 (1, 4, 8, 40 mg/kg) in mice subjected to CIA. Due to JZL184’s 
potency to significantly increase brain levels of 2-AG at a low dose (4 mg/kg), a JZL184 dose 
range was administered to determine the analgesic and anti-locomotor suppression effects of 
acute JZL184 treatment (Long et al., 2009). First, mice subjected to CIA were injected with a 
moderate (8 mg/kg) or high dose (40 mg/kg) of JZL184 (Ghosh, 2013; Kinsey et al., 2011a) or 
vehicle and testing for mechanical allodynia, spontaneous locomotor activity, followed by 
thermal hyperalgesia. Second, due to the attenuation of CIA-induced hyperalgesia in the hot 
plate test with the moderate and high doses of JZL184,  low doses of JZL184 (1 & 4 mg/kg) 
(Ghosh, 2013; Kinsey et al., 2011a) or vehicle were administered to a separate cohort of mice 
subjected to CIA. Mice were then tested for allodynia, locomotor activity, and hyperalgesia. In 
experiment 1b the FAAH inhibitor PF-3845 (10 mg/kg) (Ahn et al., 2009) or vehicle was 
administered to a separate cohort of mice subjected to CIA and mice were tested for allodynia, 
locomotor activity, and hyperalgesia. In experiment 1c a separate cohort of mice subjected to 
CIA was administered the synthetic glucocorticoid agonist dexamethasone (2 mg/kg) (Naidu et 
al., 2010) or vehicle. Mice were then tested for allodynia, locomotor activity, and hyperalgesia. 
PF-3845 and dexamethasone were used as positive controls. Both acute PF-3845 (10 mg/kg) 
(Ghosh et al., 2013) and acute dexamethasone (2 mg/kg) (Naidu et al., 2010) attenuate acute 
inflammatory pain. Separate control mice, not subjected to CIA, were also tested for allodynia, 
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locomotor activity, and hyperalgesia in each experiment.  
 The goal of the second experiment was to determine the possible cannabinoid receptor 
mechanism of action through which JZL184 attenuated CIA-induced hyperalgesia. Mice were 
administered the CB1 antagonist rimonabant (3 mg/kg, i.p.), the CB2 antagonist SR144528 (3 
mg/kg, i.p.), or vehicle. Thirty minutes later, mice were injected intraperitoneally with vehicle or 
JZL184 (40 mg/kg) and then tested for allodynia, locomotor activity, and hyperalgesia. Separate 
control mice, not subjected to CIA, were also tested for allodynia, locomotor activity, and 
hyperalgesia.  
 The goal of the third experiment was to determine the anti-inflammatory and anti-
nociceptive effects of chronic JZL184 administration. Chronic PF-3845 administration was used 
as a positive control (Kinsey et al., 2011a). The day that mice received the booster injection of 
collagen (i.e., day 21), mice were administered JZL184 (8 mg/kg, s.c.), PF-3845 (10 mg/kg, s.c.), 
or vehicle once daily, for 15 consecutive days. During chronic administration mice were assessed 
daily for gross signs of inflammation using paw swelling and clinical scores as described above. 
After the final treatment with JZL184, PF-3845, or vehicle (i.e., day 36), each mouse was tested 
for locomotor activity, allodynia, and hyperalgesia, as detailed below. Separate control mice, not 
subjected to CIA, were also administered vehicle repeatedly and tested for allodynia, locomotor 
activity, and hyperalgesia. 
 
 
Figure 2. Diagram of behavioral test battery. In each experiment, mice were administered 
drug or vehicle and tested 2 h later for mechanical allodynia in the von Frey assay, a 
locomotor assay, and thermal hyperalgesia in the hot plate and tail immersion assays. In 
Experiment 2 mice were administered cannabinoid receptor antagonists or vehicle 30 min 
before JZL184.  






Behavioral testing (allodynia, locomotor activity, and hyperalgesia) began after the 
development of inflammation in at least 1 paw (approximately 7-14 days after the “booster” 
injection of collagen). Mice were randomly assigned to a drug treatment and tested by an 
experimenter who was blinded to the treatment conditions. Due to ongoing model development 
separate cohorts of mice were used for each experiment (see Table 1). In the case where multiple 
experimenters were required, interobserver reliabilities for behavioral tests were performed 
before the experiments were conducted and were correlated to > 0.98. Mice were tested on all 
behavioral assays in one day. For experiments with JZL184 and PF-3845, significant increases in 
endocannabinoid tissue levels are present 24 h after administration of either compound (Ahn et 
al., 2009; Long et al., 2009). Dexamethasone is long acting steroid with a biological half-life of 
36 – 54 h (Ozdemir, Guvenal, Cetin, Kaya, & Cetin, 2003). The test battery was performed in the 
following order, based on the level of stress each test induces in mice, to decrease the effects of 
stress on behavior: mechanical allodynia, locomotor activity, hot plate test, and tail immersion 
test (see Figure 2). Although mechanical allodynia is more stressful than locomotor activity it 
was performed first because mice were required to acclimate for at least 60 min on the von Frey 
testing apparatus (Kinsey et al., 2009). Performing mechanical allodynia first minimized the time 
between drug administration and the last behavior assay. 
On the test day, mice were brought into the testing room, weighed, and injected. After 
receiving drug, the mice were placed in ventilated polycarbonate chambers (7.5 x 9 cm) on an 
aluminum mesh table, where they were allowed to acclimate for 120 min before testing for 
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mechanical allodynia, as detailed below. Then mice were individually placed into either a clean, 
plastic test cage to test spontaneous locomotor activity or a test cage filled with bedding and 
evenly spaced marbles to test locomotor activity using the marble burying test. Mice habituated 
to the plastic test cages, but not the test cages with bedding and evenly spaced marbles (Thomas 
et al., 2009). Therefore, for experiments where mice were repeatedly tested the marble burying 
test was used to measure locomotor activity. Immediately following locomotor activity, 
hyperalgesia response latencies were assessed in the hotplate and then tail immersion tests as 
detailed below (see Figure 2). Thus, for JZL184, PF-3845, and dexamethasone, the total 
absorption time before behavioral testing was 120 min across treatments. A 120 min absorption 
time for JZL184 was used based on previous reports that the endocannabinoid 2-AG tissue levels 
peak 2 h after administration of the compound (Long et al., 2009). A 120 min absorption time for 
PF-3845 and dexamethasone was used to keep testing consistent across experiments. For the 
receptor mechanism study, mice were pretreated with the CB1 receptor antagonist rimonabant (3 
mg/kg, i.p.), the CB2 receptor antagonist SR144528 (3 mg/kg, i.p.), or vehicle 30 min before 
receiving JZL184. The effects of the CB1 and CB2 receptors are blocked by a 3 mg/kg dose of 
rimonabant and SR144528, respectively with a 30 min pretreatment time (Lichtman, Sheltona, 
Advania, Cravatt, 2004). For the chronic dosing study, a separate cohort of mice was randomly 
assigned to drug treatment and administered JZL184 (8 mg/kg, s.c.), PF-3845 (10 mg/kg, s.c.), or 
vehicle once daily for 15 consecutive days, starting 21 days after the initial immunization. Based 
on preliminary data from our lab and previous literature we chose moderate doses of JZL184 and 
PF-3845 that attenuate inflammation and pain without the development of tolerance with 
repeated administration (Kinsey et al., 2013; Schlosburg et al., 2010). Behavioral testing was 
conducted on the last day of chronic dosing (i.e., day 15). The chronic dosing timeline was 
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chosen based on the analgesic and anti-inflammatory effects of chronic FAAH inhibition in mice 
subjected to CIA (Kinsey et al., 2011a). 
Mechanical allodynia test: Mechanical allodynia was tested using the “up-down” method 
(Chaplan, Bach, Pogrel, Chung, & Yaksh, 1994; Kinsey et al., 2009) with von Frey filaments 
(North Coast Medical, Morgan Hill, CA) to stimulate the plantar surface of each hind paw. Von 
Frey filaments are commonly used to test touch sensitivity in humans and other animals and are 
calibrated to bend at established weights. Each hind paw was stimulated approximately twice per 
second with each filament (0.16-6.0 g) five times starting with the 0.6-g filament. The filaments 
were tested in ascending order until the mouse clutched or lifted its paw. This was considered a 
positive response. Once the mouse responded positively to 3 out of 5 presentations of the 
filament, the filaments were presented in descending order to establish a sensory threshold. 
CIA-suppressed locomotor test: In addition to eliciting behavioral responses, pain can also 
suppress normal behaviors, such as locomotion. Thus, to complement the nociceptive tests, the 
total distance travelled and the total time spent immobile were also assessed, as described 
previously (Kinsey, O’Neal, Long, Cravatt, & Lichtman, 2011c). Approximately 45 min after the 
von Frey test, mice were placed individually into a clean, plastic test cage (30.80 cm x 40.60 cm 
x 15.88 cm), inside of a sound-attenuating chamber, and spontaneous locomotor activity was 
recorded for 20 minutes, using ANYmaze automated video tracking software (Stoelting, Wool 
Dale, IL).  
Marble Burying test. The marble burying test is a useful test of locomotor suppression in the 
chronic constriction injury mouse model of neuropathic pain (J. Wilkerson, personal 
communication, January 22, 2014). Unlike the spontaneous locomotor test detailed above, mice 
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do not habituate to the marble burying test (Thomas et al., 2009). Therefore, the marble burying 
test was used in place of spontaneous locomotor activity to measure locomotor suppression for 
all experiments in which mice were repeatedly tested. In the marble burying test, mice were 
placed individually into a plastic test cage (30.80 cm x 40.60 cm x 15.88 cm) filled to a depth of 
5 cm with SANI-CHIP Aspen bedding (Harlan Laboratories, Indianapolis, IN) with 25 clear, 
glass marbles (10mm in diameter) arranged in an evenly spaced, 5 x 5 grid-like pattern across the 
surface of the bedding. The cage was placed inside of a sound-attenuating chamber and 
locomotor activity was recorded for 20 minutes, using ANYmaze automated video tracking 
software (Stoelting, Wool Dale, IL). In experiments where locomotor activity was measured 
using the marble burying test, the amount of marbles buried was also assessed. Mice placed in 
the marble burying test apparatus engage in a repetitive digging behavior that leads to marbles 
being buried (Thomas et al., 2009). 
Nociceptive tests. Mice were tested for thermal hyperalgesia using the hot plate and tail 
immersion tests approximately 1 h after testing locomotor suppression. Individual mice were 
placed in a ventilated polycarbonate chamber on a hot plate that was heated to 52 ̊ C (Kinsey et 
al., 2011a; Naidu et al., 2010). The latency for each mouse to lick or shake a hind paw, to flare 
its toes, or to jump out of the apparatus, was scored as the dependent variable. Based on 
preliminary data from our lab and previous literature a 30 s cutoff time was used to avoid the 
possibility of tissue damage (Kinsey et al., 2011a). Immediately after the hot plate test, 
individual mice were placed head first into a small bag assembled from absorbent under pads, 
leaving the tail exposed (Kinsey et al., 2011a). The mouse was gently held while the distal 1 cm 
of the tail was quickly dipped into a water bath heated to 52 ̊ C. The latency for the mouse to 
withdraw its tail was scored as the dependent variable. Because water transfers heat quicker than 
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a solid surface, a shorter cutoff time of 10 s based on previous literature was used to avoid the 
possibility of tissue damage (Kinsey et al., 2011a).   
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Statistical Analyses 
 All data were analyzed by ANOVA, followed by Bonferroni post hoc, with the exception 
of the dose response data, for which Dunnett's post hoc was used instead (all doses compared 
with vehicle or non-CIA control group). For the first experiment, a one-way ANOVA of acute 
drug condition was calculated. For the second experiment, a one-way ANOVA of drug doses 
(MAGL inhibitor and CB receptor antagonist) was conducted. The third experiment was 
analyzed using a one-way ANOVA of drug doses. Differences were considered statistically 
significant if p < 0.05. 
Results 
Experiment 1a: Acute MAGL inhibitor JZL184 attenuates CIA-induced thermal 
hyperalgesia and did not affect CIA-suppressed locomotor activity at high and moderate 
doses 
Based on preliminary data from our lab and previous literature we first tested a moderate 
and high dose of JZL184 that we expected would attenuate hyperalgesia (Ghosh et al., 2013; 
Kinsey et al., 2011a). Mice were subjected to CIA (see Table 1). Eighteen percent of mice 
subjected to CIA developed significantly higher clinical scores than non-CIA controls [F (1, 38) 
= 128.6; p < .0001; Figure 3A]. Although it is expect that some mice would not respond to the 
CIA treatment, the incidence in this cohort was low, based on previous literature (Brand et al., 
2007). On test day, mice were injected with the MAGL inhibitor JZL184 (8 & 40 mg/kg, i.p.) or 
vehicle. Behavioral assays were performed 2 h after JZL184 administration, to coincide with 
peak tissue levels of 2-AG (Long et al., 2009). Acute JZL184 attenuated CIA-induced thermal 
hyperalgesia in the hot plate test [F (3, 58) = 9.3; p < .0001; Figure 3B]. Post hoc comparisons 
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revealed that JZL184 significantly reduced hyperalgesia in the hot plate test at both the 8 mg/kg 
(p < .05) and 40 mg/kg (p < .01) doses. In the tail immersion test, there was a main effect of drug 
treatment on thermal hyperalgesia [F (3, 58) = 3.04; p < .05; Figure 3C]. However, post-hoc 
comparisons revealed that CIA did not significantly increase tail withdrawal times, compared to 
controls (p = .06). Therefore, it is not surprising that acute JZL184 did not affect thermal 
hyperalgesia in the tail immersion test at either the 8 mg/kg (p = .99) or 40 mg/kg (p = 1) dose.  
For the von Frey test, there was a main effect of drug treatment on mechanical allodynia 
[F (3, 120) = 2.95; p < .05; Figure 3D] when both paws were analyzed together. However, post-
hoc comparisons revealed that CIA did not significantly increase mechanical allodynia (p = .09) 
compared to controls. Due to the lack of CIA effect, acute JZL184 did not restore mechanical 
allodynia in CIA mice at the 8 mg/kg (p = 1) or 40 mg/kg (p = .91) dose. When analyzed 
separately, there was no significant difference in mechanical allodynia in the left paws [F (3, 
120) = 2.23; p = .09] or right paws [F (3, 120) = 1.53; p = .22].  
CIA significantly suppressed locomotor activity [F (3, 1236) = 141.3; p < .0001; Figure 
3E]. However, post-hoc comparisons revealed no significant attenuation of locomotor 
suppression by acute JZL184 at the 8 mg/kg dose (p = .96) or the 40 mg/kg dose (p = .22). 
Due to the attenuation of CIA-induced hyperalgesia by a high and moderate dose of acute 
JZL184 (8 & 40 mg/kg) we next tested lower (1 & 4 mg/kg) doses of JZL184 to establish a dose 
response. However, the data was not combined into a single analysis because of difference in 
methodology (e.g. differences in CIA induction and locomotor assay performed). A low dose (4 
mg/kg) of JZL184 attenuates allodynia in an acute inflammatory pain model (Ghosh et al., 
2013), but does not reduce marble burying (Kinsey, O'Neal, Long, Cravatt, & Lichtman, 2011c). 
Therefore, JZL184 (1 mg/kg) was also used as a subthreshold dose to establish the dose response 
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(Ghosh et al., 2013; Kinsey et al., 2011c). Due to the low incidence of arthritis in the previous 
experiment, a separate cohort of mice was subjected to CIA (see Table 1). Thirty-eight percent 
of the mice subjected to CIA developed significantly higher clinical scores than non-CIA 
controls [F (2, 57) = 38.4; p < .0001; Figure 4A]. Although the incidence of arthritis was higher 
than the previous experiment, the incidence in this cohort was lower than expected, based on the 
literature (Brand et al., 2007). On test day, mice were injected with the MAGL inhibitor JZL184 
(1, 4 mg/kg), or vehicle. Two h later behavioral assays were performed. CIA did not induce 
thermal hyperalgesia [F (3, 74) = 1.79; p = .16; Figure 4B] in the hot plate test. Therefore, acute 
JZL184 had no effect. CIA did induce hyperalgesia in the tail immersion test [F (3, 74) = 5.11; p 
< .01; Figure 4C]. However, post-hoc comparisons revealed no significant attenuation of 
hyperalgesia of acute JZL184 at the 1 mg/kg or the 4 mg/kg dose.   
CIA induced mechanical allodynia when both paws were analyzed together [F (3, 88) = 
10.46; p < .0001; Figure 4D], but post-hoc comparisons revealed there was no significant 
decrease of allodynia by acute JZL184 at the 1 mg/kg or 4 mg/kg dose. When paws were 
analyzed separately, there was a significant difference in mechanical allodynia in the right paws 
[F (3, 40) = 7.11; p < .01], and the left paws [F (3, 40) = 4.36; p < .05]. Post-hoc comparisons 
revealed there was no significant decrease of allodynia in CIA mice in the right paw or the left 
paw at either the 1 mg/kg or 4 mg/kg dose.   
CIA reduced marbles buried [F (3, 62) = 8.193; p < .001; Figure 4E], but post-hoc 
comparisons revealed no significant restoration of marbles buried at the 1 mg/kg or 4 mg/kg dose 
of acute JZL184. CIA did not suppress locomotor activity in the marble burying test [F (3, 62) 
=.745; p =.53; Figure 4F]. Due to the lack of CIA effect, post-hoc comparisons revealed no 
significant attenuation of locomotor suppression by acute JZL184.  
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Experiment 1b: Acute FAAH inhibitor PF-3845 does not affect CIA-induced thermal 
hyperalgesia or CIA-suppressed locomotor activity 
In the next experiment, we tested the FAAH inhibitor PF-3845 to compare to JZL184 as a 
positive control. FAAH inhibition was expected to attenuate CIA-induced hyperalgesia based on 
previous literature (Kinsey et al., 2011a). We chose the dose of PF-3845 administered in the 
present study based on the attenuation of allodynia by acute PF-3845 (10 mg/kg) administration 
in the mouse carrageenan model of acute inflammatory pain (Ghosh et al., 2013). A separate 
cohort of mice was subjected to CIA because of the low incidence of arthritis in the acute 
JZL184 experiments (see Table 1). Ninety percent of the mice developed significantly higher 
clinical scores than non-CIA controls [F (2, 47) = 22.96; p < .0001; Figure 5A], as expected. On 
test day, mice were injected with the FAAH inhibitor PF-3845, or vehicle. To keep methods 
consistent as possible despite model development behavioral assays were performed 2 h later. 
CIA did not induce thermal hyperalgesia in the hot plate [F (2, 29) = .66; p = .52; Figure 5B] 
and tail immersion tests [F (2, 29) =.52; p = .60; Figure 5C]. Therefore, acute PF-3845 had no 
effect in the hot plate or tail immersion tests.  
CIA induced mechanical allodynia when both paws were analyzed together [F (2, 61) = 
5.32; p < .01; Figure 5D] but, post-hoc comparisons revealed that acute PF-3845 did not 
significantly decrease allodynia. When analyzed separately, there was not a significant difference 
in mechanical allodynia in the right paws [F (2, 29) = 2.07; p = .14] or the left paws [F (2, 29) = 
3.06; p = .06].  
CIA did not reduce marbles buried [F (2, 24) = 3.15; p = .06; Figure 5E]. PF-3845 had 
no effect on the number of marbles buried. However, there was a main effect of drug treatment 
on locomotor activity in the marble burying test [F (2, 29) = 5.99; p < .01; Figure 5F], but post-
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hoc comparisons revealed no CIA-suppressed locomotor activity. PF-3845 had no effect on 
locomotor activity. 
 
Experiment 1c: Acute dexamethasone does not affect CIA-induced thermal hyperalgesia or 
CIA-suppressed locomotor activity 
Due to the inconsistencies in the behavioral effects with the administration of acute PF-
3845 we next tested the steroid dexamethasone as an alternative positive control. Acute 
dexamethasone (2 mg/kg) attenuates hyperalgesia in the mouse LPS model of acute 
inflammatory pain (Naidu et al., 2010). A separate cohort of mice was subjected to CIA, because 
of the inconsistencies in behavioral effects between CIA and control mice in the previous 
experiments (see Table 1). Seventy-seven percent of the mice developed significantly higher 
clinical scores than non-CIA controls [F (2, 26) = 17.4; p < .0001; Figure 6A]. On test day, mice 
were injected with the glucocorticoid dexamethasone (2 mg/kg), or vehicle. Behavioral assays 
were performed 2 h later. CIA did not induce thermal hyperalgesia in the hot plate [F (2, 21) = 
.72; p = .50; Figure 6B] and tail immersion tests [F (2, 21) = 1.43; p = .26; Figure 6C]. Acute 
dexamethasone had no effect in either test. 
CIA did not induced mechanical allodynia when both paws were analyzed together [F (2, 
45) = .31; p = .73; Figure 6D]. Due to the lack of CIA effect, acute dexamethasone did not 
reverse mechanical allodynia. This lack of significant difference in mechanical allodynia was 
maintained when paws were analyzed separately in the right paws [F (2, 21) = .15; p = .86] or 
the left paws [F (2, 21) = .15; p = .86].  
CIA reduced marbles buried [F (2, 21) = 4.67; p < .05; Figure 6E], but post-hoc 
comparisons revealed no significant effect of dexamethasone. CIA mice did not display 
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locomotor suppression in the marble burying test [F (2, 21) =.427; p = .66; Figure 6F]. Acute 
dexamethasone had no effect on locomotor activity in the marble burying test.  
 
Experiment 2: Receptor mechanism of action of MAGL inhibition by JZL184 attenuation 
of CIA-induced hyperalgesia is unclear 
In the next experiment, we tested the cannabinoid receptor mechanism of action of the 
high dose of JZL184 (40 mg/kg) in attenuating CIA-induced hyperalgesia, per the results of the 
first experiment. Again, due to inconsistencies in the CIA effects compared to controls in the 
previous experiments, a separate cohort of mice was subjected to CIA (see Table 1). Sixty-six 
percent of the mice subjected to CIA developed significantly higher clinical scores than non-CIA 
controls [F (2, 87) = 73.01; p < .0001; Figure 7A]. In order to assess the receptor mechanism of 
action underlying the antihyperalgesic effects of acute JZL184 (40 mg/kg), mice were pretreated 
with the selective CB1 antagonist rimonabant (3 mg/kg), the selective CB2 antagonist SR144528 
(3 mg/kg), or vehicle 30 min before receiving JZL184. The dosing and pre-treatment times of the 
cannabinoid receptor agonists was chosen based on previous literature (Lichtman et al., 2004). 
CIA did not induce thermal hyperalgesia in the hot plate test [F (4, 55) = .31; p = .87; Figure 
7B]. Due to the lack of CIA effect, neither JZL184 nor the antagonists had any effect in the hot 
plate test. There was a main effect of drug treatment in the tail immersion test [F (4, 55) = 3.98; p 
< .05; Figure 7C], but post-hoc comparison revealed that CIA did not induce thermal 
hyperalgesia in the tail immersion test. However, in the tail immersion test JZL184 increased tail 
withdrawal latency in CIA mice. The increase by JZL184 was not reversed by rimonabant or 
SR144528.  
CIA induced mechanical allodynia [F (4, 55) = 14.65; p < .0001; Figure 7D] when both 
paws were analyzed together. Post-hoc comparisons revealed that JZL184 (40 mg/kg) did not 
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restore allodynia. When analyzed separately, there was a significant difference in mechanical 
allodynia in the right paws [F (4, 55) = 7.54; p < .0001], but not the left paws [F (4, 55) = 2.14; p 
= .09].  
CIA reduced marbles buried [F (4, 55) = 18.77; p < .0001; Figure 7E]. However, post-
hoc comparisons revealed an additional decrease in marbles buried caused by acute JZL184 (40 
mg/kg) that was not blocked by rimonabant or SR144528. This decrease in marble burying was 
in line with published effects of this high dose of JZL184 in marble burying (Kinsey et al., 
2011c). There was a main effect of drug treatment in locomotor activity in the marble burying 
test [F (4, 55) = 7.820; p < .0001; Figure 7F], that was driven by JZL184 (40 mg/kg) and was 
not reversed by rimonabant or SR144528.  
 
Experiment 3: Chronic MAGL or FAAH inhibition does not affect CIA-induced 
hyperalgesia or inflammation 
We next tested the effects of chronic MAGL and FAAH inhibition. Chronic MAGL and 
FAAH inhibition attenuates inflammation (Kinsey et al.,2011a; Kinsey et al.,2011b). Therefore, 
we hypothesized that attenuating inflammation would improve behavioral outcomes in CIA 
mice. A separate cohort of mice was subjected to CIA (see Table 1). Ninety-eight of mice 
subjected to CIA developed significantly higher clinical scores than non-CIA controls [F (3, 43) 
= 5.596; p = .0025; Figure 8A]. However, post-hoc comparisons revealed no significant 
difference in clinical scores with drug treatment. Mice were administered the MAGL inhibitor 
JZL184 (8 mg/kg, s.c.), the FAAH inhibitor PF-3845 (10 mg/kg, s.c.), or vehicle once daily for 
15 consecutive days. Drug administration started on “booster” collagen exposure day (21 days 
after the initial immunization; Kinsey et al., 2011a). Repeated administration of moderate doses 
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of JZL184 (8 mg/kg) (Kinsey et al., 2013) or PF-3845 (10 mg/kg) (Schlosburg et al., 2010) 
maintains anti-allodynic effects in a mouse model of neuropathic pain for 5 and 6 days, 
respectively. On day 15, mice were injected again, and behavioral assays were performed 2 h 
later.  
CIA did not induce thermal hyperalgesia in the hot plate [F (3, 44) = .18; p = .91; Figure 
8B] or tail immersion test [F (3, 44) = .28; p = .84; Figure 8C]. Neither chronic PF-3845 nor 
JZL184 had any effect on hyperalgesia.  
CIA mice did not display mechanical allodynia, compared to control mice [F (3, 44) = 
2.569; p = .06; Figure 8D] when both paws were analyzed together. When analyzed separately, 
there was a main effect of drug treatment on mechanical allodynia in the left paws [F (3, 44) = 
3.232; p <.03], but not the right paws [F (3, 44) = .552; p <.65] of mice. However, post-hoc 
comparisons revealed that CIA did not induce mechanical allodynia in the left paw. PF-3845 and 
JZL184 had no effect on allodynia.  
There was a main effect of suppressed locomotor activity in the spontaneous locomotor 
activity test [F (3, 44) = 4.32; p < .01; Figure 8E]. Surprisingly, post-hoc comparisons revealed 




 The goal of this study was to test the hypothesis that inhibition of MAGL would decrease 
hyperalgesia and locomotor suppression in mice subjected to collagen induced arthritis (CIA). 
Acute administration of the selective MAGL inhibitor JZL184 (8 & 40 mg/kg) attenuated CIA-
induced thermal hyperalgesia in the hot plate test, but not the tail immersion test. JZL184 (8 & 
40 mg/kg) did not reverse CIA-induced locomotor suppression or affect mechanical allodynia. 
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Conversely, acute administration of the selective FAAH inhibitor PF-3845, the selective MAGL 
inhibitor JZL184 (1& 4 mg/kg), or the glucocorticoid dexamethasone did not significantly affect 
any of our outcome measures. 
 The second objective of this study was to determine cannabinoid receptor involvement in 
the attenuation of CIA-induced hyperalgesia by acute JZL184 administration. There was 
insufficient CIA induction of hyperalgesia or locomotor suppression to determine cannabinoid 
receptor involvement in acute JZL184 attenuation of CIA-induced hyperalgesia. In the tail 
immersion test, acute JZL184 administration increased the latency to respond in the CIA-treated 
mice, but neither the CB1 receptor antagonist rimonabant nor the CB2 receptor antagonist 
SR144528 reversed the effect of JZL184. CIA induced mechanical allodynia that was not 
restored by acute JZL184. Similarly, CIA reduced the number of marbles buried, and this 
reduction was unaffected by acute JZL184.  
 The third objective of this study was to evaluate the effects of chronic administration of 
the selective MAGL inhibitor JZL184 and the selective FAAH inhibitor PF-3845 in CIA-induced 
hyperalgesia, allodynia, and locomotor suppression. There was insufficient CIA induction of 
hyperalgesia, allodynia, or locomotor suppression on the behavioral test day to determine the 
effects of chronic dosing.  
 The present study is the first to show that acute MAGL inhibition reduces thermal 
hyperalgesia in a mouse model of inflammatory arthritis. The reduction of inflammatory pain by 
acute MAGL inhibition is consistent with previous reports that the MAGL inhibitors JZL184 and 
KML29 attenuate carrageenan-induced acute inflammatory pain (Gosh et al., 2013; Ignatowska-
Jankowska et al., 2013). These studies, taken together with the present data, suggest that acute 
MAGL inhibition reduces both chronic and acute inflammatory pain.  
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 However, there are inconsistencies with the reduction in pain elicited by acute MAGL 
inhibition in the present study. One potential reason for the inconsistency in results is the 
problems experienced with CIA model itself. As detailed in Table 1, the CIA model was still 
being optimized throughout the present studies. After the initial CIA immunization, it typically 
took 4-8 weeks for the mice to develop arthritis. CIA induction normally results in 80-100% of 
mice developing arthritis in at least one paw (Brand et al., 2007). In the present study, less than 
50% of the mice developed CIA in the first few cohorts. The mice in these cohorts were used to 
test acute JZL184 (8 & 4 mg/kg) to make progress on this thesis while continuing with model 
development. Therefore, changes were made to increase the concentration of bacteria and 
heaviness of the CFA oils in each successive cohort of mice. In addition, seemingly minor 
adjustments to the methodology, such as using a stopcock to minimize the introduction of air in 
the emulsion when drawing into the syringe, turned out to be very important. This 
methodological fine tuning resulted in an arthritic incidence rate of over 90%. However, the CIA 
was more extreme, and with a more rapid onset than in previous cohorts of mice, and may have 
contributed to the lack of an anti-inflammatory effect in the chronic dosing study (thus not 
replicating previously published reports), which was run later than the acute JZL184 studies. 
Moreover, the concern now is that the CIA no longer reflects human inflammatory arthritis. 
Model development is still in progress, with the goal of finding the optimal concentration and 
consistency of CFA to induce a consistently high incidence of arthritis, and we continue to 
correspond with helpful consultants as we troubleshoot the model. After optimizing the CIA 
model, the next step will be to replicate the present studies, with the goal of obtaining more 
consistent, and potentially publishable, results. If nothing else, the inconsistency of the CIA 
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model in the present study taught me that careful planning and preparation do not necessarily 
translate into research proceeding according to plan.  
 JZL184 attenuated CIA-induced pain in some experiments but not others, and depended 
on the pain assay. On the hot plate test, acute JZL184 (8 & 40 mg/kg) attenuated hyperalgesia. 
Although these results did not repeat in the receptor mechanism experiment, acute JZL184 (40 
mg/kg) did reduce CIA-induced hyperalgesia in pilot groups of mice (please see Appendix A). 
This inconsistency is plausibly due to the use of the highly virulent CIA that was induced when 
testing receptor mechanisms. Thus, because of their highly inflamed and calcified joints, the 
mice may have had a difficult time licking or shaking their hind paws to indicate hyperalgesia. In 
support of this idea, CIA mice did not display increased hyperalgesia in any assay of the receptor 
mechanism study. In my current work, I am exploring other dependent variables that may help 
get at joint function, such as locomotor coordination in the rotarod test, as well as more localized 
pain tests, such as the acetone-induced cold allodynia test and the Hargreaves plantar stimulator 
test. 
 Similarly, although the tail immersion test is also an assay of thermal hyperalgesia, there 
was no significant effect of JZL184, and even the CIA effect was inconsistent. This lack of an 
effect could be due to the differences in the neural pathways. The hot plate test measures a 
supraspinal response; whereas the tail immersion test measures a spinal reflex (Le Bars, Gozariu, 
& Cadden, 2001). JZL184 also failed to attenuate CIA-induced mechanical allodynia in the von 
Frey test. Inflammation may not develop in all four paws of a CIA-induce mouse (Brand, 2007).  
Therefore, in the present study inflammation was not present in every hind paw even though all 
of the mice tested in the acute dosing experiments developed CIA symptoms. In the von Frey test 
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the threshold for both hind paws was measured. Therefore, inconsistent inflammation could be a 
reason why mechanical allodynia was not present across all experiments.  
 Many patients experiencing chronic pain, such as those with rheumatoid arthritis (RA) 
have problems with mobility (Laroche, Poxxo, Ornetti, Tavernier, & Maillefert, 2006). As in 
humans, CIA induced locomotor suppression in the present study. Because mice quickly 
habituate to the spontaneous locomotor activity test, the marble burying test was used to measure 
locomotor activity for the latter experiments in the present study. CIA did not reliability suppress 
locomotor activity, and so it is not surprising that JZL184 was unable to reverse this lack of 
locomotor suppression in the marble burying test. However, locomotor activity may have been 
confounded by the order of the behavioral assays. The von Frey test requires mice to acclimate 
for 60 min a wire mesh apparatus before testing (Kinsey et al., 2009). Therefore, in the present 
study the von Frey test was performed prior to locomotor activity to minimize time between drug 
administration and the last behavioral assay. It is possible that standing on the wire mesh and 
stimulation of hind paws with the von Frey filaments affected the locomotor activity of the mice. 
In the future we plan on assessing locomotor activity first to limit confounds. An alternative is to 
test motor coordination, which may grant some insights into loss of motor function as a result of 
CIA. The rotarod is a test of motor coordination where a mouse is placed on a rotating rod and 
the latency to fall off the rod is measured (Kinsey et al., 2011d). Drugs that affect motor 
coordination, such as ethanol and THC, significantly reduce the latency to fall from the rotarod. 
Since running the present studies, my lab purchased a rotarod, and I have found that CIA mice 
spend less time on the rotarod at a fixed speed (please see Appendix B).  
 The finding in the present study that the CB1 receptor antagonist rimonabant or the CB2 
receptor antagonist SR144528 did not reverse the effects of JZL184 is most likely due to 
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inconsistencies with the CIA model in the present study. Indeed, there was not a significant 
difference between the CIA and control mice used to test cannabinoid receptor mechanisms in 
hyperalgesia and locomotor activity. An alternative, albeit less plausible explain for the lack of 
JZL184 reversal is a non-cannabinoid mechanism of action. In CIA mice JZL184 did increase 
the latency of mice to withdraw their tails from the water compared to vehicle in the tail 
immersion test. However, neither the CB1 nor the CB2 receptor antagonist reversed the JZL184 
increase in latency. In addition to CB1 and CB2 receptors cannabinoids will also bind to other 
receptors such as the orphan G protein–coupled receptor GPR55, transient receptor potential 
vanilloid receptor (TRPV1), and peroxisome proliferator-activated receptors (PPAR) (Howlett, 
2002). However, JZL184 attenuates allodynia in the carrageenan model of acute inflammatory 
pain through a mechanism that requires both CB1 and CB2 receptors (Gosh, 2013), indicating that 
JZL184 modulation of inflammatory pain likely occurs through a cannabinoid receptor 
mechanism. I predict that, in my future studies, JZL184 will attenuate pain in a chronic model of 
inflammatory pain through a similar mechanism of action. 
 Based on the observation that acute MAGL inhibition with JZL184 (40 mg/kg) attenuated 
thermal hyperalgesia on the hot plate test; it was surprising that chronic JZL184 did not attenuate 
CIA-induced thermal hyperalgesia. As with the antagonist study, the inconsistencies between 
acute and chronic dosing of JZL184 in attenuating thermal hyperalgesia may be due to the use of 
the more virulent CIA. Again, the mice appeared to have difficulty licking or shaking their hind 
paws, both of which are dependent variables that we operationally defined to indicate 
hyperalgesia. In support of this idea, the CIA mice did not display increased hyperalgesia. 
Another possible contributing factor is that chronic JZL184 administration started too late to 
attenuate CIA induced hyperalgesia. In other words, the mice may have started developing 
Analgesic Effects in Collagen-Induced Arthritis   36 
 
arthritis before they received any drug. Chronic dosing was started on day 21 after the initial 
immunization, but mice started developing swelling and paw inflammation only a few days after 
chronic JZL184 dosing started. A third possible explanation is that mice developed tolerance to 
chronic JZL184 administration. Repeated administration of high doses of JZL184 (16 & 40 
mg/kg) reduced its anti-allodynic effects after 5 days in a mouse model of neuropathic pain 
(Kinsey et al., 2013; Schlosburg et al., 2010). Although the low dose of JZL184 (8 mg/kg) used 
in the present study did not show tolerance in the previous reports, the effects of a 15 day 
treatment of JZL184 are unknown. A possible solution to the problem of JZL184 tolerance 
would be to use a lower dose of JZL184 or to genetically delete MAGL. MAGL (-/-) mice are 
not yet commercially available, although my advisor, Dr. Kinsey, has received notice from Dr. 
Benjamin Cravatt, who designed these mice, that he will make breeders available to my lab, as 
needed. 
 The observation that neither acute nor chronic FAAH inhibition affected hyperalgesia in 
mice subjected to CIA was surprising, because chronic administration of the FAAH inhibitor 
URB597 or genetic deletion of FAAH attenuated CIA-induced hyperalgesia in the hot plate and 
tail immersion tests (Kinsey et al., 2011a). One possible explanation of the disparities between 
the current findings and those by Kinsey et al. (2011a) may be due to differences in CIA 
immunization (chicken vs. bovine collagen) and other unknown issues with CIA model 
development in the present study. CIA induction for chronic dosing testing in the present study 
was virulent and resulted in severe swelling across all treatment groups. It is possible that the 
CIA in the present study was too intractable to be attenuated by chronic FAAH or MAGL 
inhibition.  
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 In addition to the behavioral assays performed in the present study, it would be 
informative to examine the endocannabinoid and immune cell profile of the CIA joints. RA is 
characterized by swelling, inflammation, pain, tenderness, and destruction of the cartilage in the 
synovial joints (i.e., knees, elbows, wrists, hips, and fingers) (Scott, 2010). Similar to RA 
patients, mice subjected to CIA have increased T-cell and pro-inflammatory cytokine response in 
their synovial joints and cartilage destruction (Bendele, 2001). Genetic deletion of FAAH 
reduces inflammation and cartilage destruction in CIA knee joints (Kinsey et al., 2011). 
Furthermore, the exogenous cannabinoid cannabidiol decreases TNF-α production in CIA 
synovial cells (Malfait et al., 2000). These studies indicate that MAGL inhibition might also 
reduce CIA-induced joint inflammation and cartilage destruction. In a subset of the present 
studies, we harvested knee joints for histology, and these samples await future analysis. 
 In conclusion, the present findings indicate that acute pharmacological inhibition of 
MAGL reduces thermal hyperalgesia in mice subjected to the CIA model of inflammatory 
arthritis. These data provide the first evidence that MAGL inhibition attenuates pain in a model 
of inflammatory arthritis and indicate that inhibition of MAGL is a potential targets for the 
development of analgesic therapeutics for chronic inflammatory pain. 
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Figure 1. Schematic drawing of endocannabinoid metabolism. The endocannabinoid 2-
arachidonoylglycerol (2-AG) is metabolized by the enzyme monoacylglycerol lipase (MAGL) 
into glycerol and arachidonic acid (AA). Pharmacological inhibition of MAGL with the 
compound JZL184 indirectly increases brain levels of 2-AG by blocking its metabolism. 
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Figure 3. The MAGL inhibitor JZL184 (8 & 40 mg/kg) reduced hyperalgesia in mice subjected 
to collagen-induced arthritis (CIA). Mice were subjected to CIA, and 18% of CIA mice 
developed arthritic symptoms. Clinical scores for mice were measured (A). Mice were injected 
i.p. with JZL184 (8 & 40 mg/kg). Mice were tested for thermal hyperalgesia on the hot plate (B) 
and tail immersion (C) tests. Mechanical allodynia was tested via the von Frey test (D). 
Locomotor suppression was tested via spontaneous locomotor activity test (E). Data expressed as 
mean ± SEM (n = 14-16).  * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. vehicle control mice. 
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Figure 4. The MAGL inhibitor JZL184 (1 & 4 mg/kg) did not affect hyperalgesia, allodynia, or 
locomotor activity in mice subjected to collagen-induced arthritis (CIA). Mice were subjected to 
CIA, and 38% of CIA mice developed arthritic symptoms. Clinical scores for mice were 
measured (A). Mice were injected i.p. with JZL184 (1 & 4 mg/kg). Mice were tested for thermal 
hyperalgesia on the hot plate (B) and tail immersion (C) tests. Mechanical allodynia was tested 
via the von Frey test (D). Marbles buried (E) and locomotor suppression (F) was tested via the 
marble burying test. Data expressed as mean ± SEM (n = 9-21).  * p < 0.05 vs. vehicle CIA 
mice; # p < 0.05 vs. vehicle control mice. 
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Figure 5. The FAAH inhibitor PF-3845 did not affect hyperalgesia, allodynia, or locomotor 
activity in mice subjected to collagen-induced arthritis (CIA). Mice were subjected to CIA, and 
90% of CIA mice developed arthritic symptoms. Clinical scores for mice were measured (A). 
Mice were injected i.p. with PF-3845 (10 mg/kg). Mice were tested for thermal hyperalgesia on 
the hot plate (B) and tail immersion (C) tests. Mechanical allodynia was tested via the von Frey 
test (D). Marbles buried (E) and locomotor suppression (F) was tested via the marble burying 
test. Data expressed as mean ± SEM (n = 8-12).  * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. 
vehicle control mice. 
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Figure 6. The glucocorticoid dexamethasone (DEX) did not affect hyperalgesia, allodynia, or 
locomotor activity in mice subjected to collagen-induced arthritis (CIA).  Mice were subjected to 
CIA, and 77% of CIA mice developed arthritic symptoms. Clinical scores for mice were 
measured (A). Mice were injected i.p. with DEX (2 mg/kg). Mice were tested for thermal 
hyperalgesia on the hot plate (B) and tail immersion (C) tests. Mechanical allodynia was tested 
via the von Frey test (D). Marbles buried (E) and locomotor suppression (F) was tested via the 
marble burying test. Data expressed as mean ± SEM (n = 8).  * p < 0.05 vs. vehicle CIA mice; # 
p < 0.05 vs. vehicle control mice. 
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Figure 7. The MAGL inhibitor JZL184 did not affect hyperalgesia, allodynia, or locomotor 
activity in mice subjected to collagen-induced arthritis (CIA). Therefore, rimonabant (3 mg/kg) 
and SR144528 (3 mg/kg) did not block JZL184 effects. Mice were subjected to CIA, and 66% of 
CIA mice developed arthritic symptoms. Clinical scores for mice were measured (A). Mice were 
injected i.p. with JZL184 (40 mg/kg). Mice were tested for thermal hyperalgesia on the hot plate 
(B) and tail immersion (C) tests. Mechanical allodynia was tested via von Frey test (D). Marbles 
buried (E) and locomotor suppression (F) was tested via the marble burying test. Data expressed 
as mean ± SEM (n = 12).  * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. vehicle control mice. 
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Figure 8. Chronic dosing of the MAGL inhibitor JZL184 and the FAAH inhibitor PF-3845 did 
not affect hyperalgesia, allodynia, or locomotor activity in mice subjected to collagen-induced 
arthritis (CIA). Mice were subjected to CIA, and 98% of CIA mice developed arthritic 
symptoms. Clinical scores for mice were measured (A). Mice were injected s.c. with JZL184 (8 
mg/kg) or PF-3845 (10 mg/kg) for 15 days. Mice were tested for thermal hyperalgesia on the hot 
plate (B) and tail immersion (C) tests. Mechanical allodynia was tested via the von Frey test (D). 
Locomotor suppression was tested via spontaneous locomotor activity test (E). Data expressed as 
mean ± SEM (n = 8-14).  * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. vehicle control mice. 
  




Figure A1. The MAGL inhibitor JZL184 reduced hyperalgesia and suppressed locomotor 
activity in mice subjected to collagen-induced arthritis (CIA). Mice were subjected to CIA, and 
55% of CIA mice developed arthritic symptoms. Approximately 100 µl of an emulsion 
consisting of type II chicken collagen, dissolved in 0.1 M acetic acid, in an equal volume of 
complete Freund’s adjuvant (CFA) was injected subcutaneously near the base of the tail. 14 days 
later, mice were given a "booster" exposure to collagen in an equal volume of incomplete 
Freund’s adjuvant (IFA), as detailed above. 1 month later, mice were given a secondary 
"booster" exposure to type II bovine collagen in an equal volume of CFA into the tail. Mice were 
injected i.p. with JZL184 (8 & 40 mg/kg). Mice were tested for thermal hyperalgesia on the hot 
plate (A) test. Locomotor suppression was tested via spontaneous locomotor activity test (B). 
Data expressed as mean ± SEM (n = 12-13).  * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. 
vehicle baseline mice. 
  




Figure B1. Collagen-induced arthritis (CIA) reduced motor coordination. The rotarod test was 
used to measure motor coordination. Mice were placed in individual lanes on a rod rotating at 4 
RPM. Latency to fall off the rod was measured as the dependent variable. Data expressed as 
mean ± SEM (n = 8-15).  * p < 0.05 vs. vehicle control mice. 
 
